Lift BioSciences Announces Abstract Publications at the American Society of
Clinical Oncology (ASCO) Annual Meeting
London, 24 May 2024 - LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly
emerging biotech company about to start clinical trials for its first-in-class
allogeneic innate cell therapy, today announces the publication of two online
abstracts at the annual American Society of Clinical Oncology, to be held from
31 May to 4 June 2024 in McCormick Place Convention Centre in Chicago, Illinois,
US.
Abstract Publications:
1. Title: Immuno-Modulatory Alpha Neutrophils: The first-in-class
neutrophil progenitor-based allogeneic immuno-cell therapy with cytotoxic and
immunomodulatory functionality for the treatment of solid tumours
Authors: Aoife McGinley, Samuel Florence, Martin James Woodward, Durva Patel,
Andrew Willis, Alex Blyth, Alfonso Quintas-Cardama, Oxana Polyakova; LIfT
Biosciences Ltd., London, United Kingdom; LIfT Biosciences, London, United
Kingdom; Foghorn Therapeutics, Cambridge, MA
Abstract number: e14523
Session type: Publication only
Session title: Developmental Therapeutics-Immunotherapy
2. Title: Example of a simple and scalable manufacturing process for
Immuno-Modulatory Alpha Neutrophils, a specifically designed immuno-cell therapy
with direct and indirect anti-cancer activity for solid tumour indications
Authors: Durva Patel, Samuel Florence, Aoife McGinley, Jakub Lich, Urvi Thacker,
Alex Blyth, Andrew Willis, Alfonso Quintas-Cardama, Oxana Polyakova; LIfT
Biosciences Ltd., London, United Kingdom; LIfT Biosciences, London, United
Kingdom; Foghorn Therapeutics, Cambridge, MA
Abstract number: e14512
Session type: Publication only
Session title: Developmental Therapeutics-Immunotherapy
Full versions of the abstracts are available at: asco.org/abstracts.
Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: "We are
pleased to have two of our abstracts accepted for online publication at this
year's ASCO Annual Meeting, a premier meeting bringing together leaders in the
oncology field. Our abstracts show how our manufacturing process not only
enhances the efficiency and scalability of our treatments, but also ensures
production of the highest quality of therapeutic cells. Our findings demonstrate
the successful multimodal mechanisms of action of our IMANs and their capability
to immunomodulate the solid tumour microenvironment for long-lasting tumour
control, bringing us one step closer to a treatment for solid tumours and
sustained clinical benefit for patients. This acceptance signifies the strides
our team continue to make in advancing our IMANs towards the clinic and we are
glad to share this with the scientific community."
-End-
About LIfT BioSciences
LIfT BioSciences is a biotech bringing to market a first-in-class alpha
neutrophil cell therapy that overcomes the limitations of current therapies in
solid tumours by destroying tumours both directly and indirectly. LIfT's
Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment
against the tumour as they recruit the rest of the immune system to destroy the
tumour to give a durable response and lasting immunity. The patented
breakthrough N-LIfT platform is produced from a patented process using
exceptional stem cells (iPSC or HSC), a proprietary enhancement media and
genetic engineering (e.g. CARs).
LIfT is working towards expanding LIfT's immunomodulatory therapy approach into
other therapeutical areas such immunology and inflammation, and antimicrobial
resistance. LIfT is committed to delivering complete remission in high unmet
need solid tumours before the decade is out. LIfT BioSciences was founded by
Alex Blyth following the death of his mother to pancreatic cancer. See
www.liftbiosciences.com.
Further information
Investors & Media:
ablyth@LIfTBioSciences.com
(mailto:ablyth@LIfTBioSciences.com)
Alex Blyth liftbiosciences@consilium-comms.com
ICR Consilium
Mary-Jane Elliott,
Namrata Taak, Lindsey
Neville +44 (0)7718 759116
Â